Avutometinib/Defactinib hydrochloride

艾沃美替尼/盐酸地法替尼

Report date: 2025/06/18 16:36:15

Base Information

Drug NameAvutometinib/Defactinib hydrochloride
Drug Alias NameAvutometinib/Defactinib hydrochloride co-pack艾沃美替尼/盐酸地法替尼共包装产品AVMAPKI FAKZYNJA CO-PACK
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsRAF serine/threonine protein kinase inhibitorsFocal adhesion kinase 1 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1RAF serine/threonine protein kinaseFocal adhesion kinase 1
Therapy Area/IndicationsUterine Cervical NeoplasmsOvarian Neoplasms
Global Approved IndicationsUterine Cervical NeoplasmsOvarian Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/05/08
Country/TerritoryUnited States
CombinationsYes AvutometinibDefactinib hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVerastem Inc
China Registration ClassN/A

Develop Information

Active CompaniesVerastem Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A